GlassScriptPhysician profile
Akiva Diamond
NPI 1770902579
$3,632.87
in general payments reported to CMS, 2019-2025
13 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $32.56 · 2022: $56.15 · 2023: $1,698 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,372.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,713.28 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,687.75 | 2019-2025 | Calquence |
| Genzyme Corporation | $46.20 | 2019-2022 | |
| Celgene Corporation | $32.75 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $23.00 | 2019 | |
| Astellas Pharma US INC | $21.65 | 2019 | |
| Taiho Oncology, INC. | $19.39 | 2019 | |
| Puma Biotechnology, INC. | $19.28 | 2020 | |
| Merck Sharp & Dohme LLC | $17.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2019 | |
| Dova Pharmaceuticals | $13.28 | 2020 | |
| Genentech USA, INC. | $11.99 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akiva Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.